Abstract: The present invention relates to a composition for preventing or treating diseases caused by mitochondrial dysfunction, containing, as an active ingredient, an isoquinoline derivative compound represented by chemical formula 1, or a pharmaceutically acceptable salt thereof, and does not induce mitochondrial damage, unlike conventional mitochondrial toxins such as CCCP, and specifically and excellently promotes the activity of mitophagy to alleviate mitochondrial disfunction, and thus can be effectively used in the treatment of diseases caused by mitochondrial dysfunction.

Abstract: The present invention relates to a medical information query and input method, and a program and a system for performing same, and provided are a medical information query and input method, and a program and a system for performing same, the medical information query and input method comprising the steps of: retrieving, from a database, a patient’s medical information prior to a reference date; generating, from the patient’s medical information, each object by date according to a set field item; and serially displaying, on an interface, each of the objects in a separate section form by date in a corresponding field.

Abstract: The present invention relates to a medical information query and input method, and a program and a system for performing same. Provided are a medical information query and input method and a program and a system for performing same, the medical information query and input method including, a step for retrieving, from a database, medical information about a patient before a reference date; a step for generating, from the patient's medical information, an object for each date according to a set field item; and a step for displaying, on an interface, each of the objects in a separate section format, by date in a time series in the corresponding fields.

Abstract: Disclosed herein is a therapeutic agent for chronic heart failure comprising, as an effective ingredient, 5-[2-propyloxy-5-(1-methyl-2-pyrrolidinyl-ethylamidosulfonyl)phenyl]-1-methyl-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidine-7-one. The compound inhibits phosphodiesterase-5 (PDE-5), which catalyzes the intracellular degradation of cyclic guanosine monophosphatase (cGMP), thereby mitigating several signs of chronic heart failure, that is, thereby preventing left ventricular dilatation, decreasing ventricular wall thinning, lowering elevated cardiac and circulating levels of atrial natriuretic peptide (ANP), and inhibiting ventricular fibrosis. Also, the compound has advantages in that it reaches the maximal plasma level in a short time, has an in vivo half-life longer than conventional PDE-5 inhibitors, allowing decreased administration frequency, and has fewer side effects, thus ensuring safety. Thus, the compound is useful as a therapeutic agent for chronic heart failure.